Samsung Epis Invests 20 Billion Won in G2G Bio...Partners on Obesity Treatment

Joint Development of Long-acting Semaglutide-based Obesity Treatment
Exclusive Rights to Two Obesity Drug Candidates and Priority Negotiation for Further Development

Samsung Bioepis and Episnex Lab are joining forces with G2G Bio to co-develop obesity treatments.

On March 16, Samsung Epis Holdings announced that its subsidiaries, Samsung Bioepis and Episnex Lab, have signed a joint research and license agreement with G2G Bio for the development of long-acting obesity treatments.

The purpose of this agreement is to develop long-acting obesity medications by utilizing G2G Bio's microsphere-based drug delivery technology. Samsung Bioepis will introduce and drive the development and commercialization of G2G Bio's pipeline. Episnex Lab will conduct joint research to build a platform for long-acting drug delivery technology.

Incheon Songdo Samsung Bioepis Headquarters. Samsung Bioepis

Samsung Bioepis has secured exclusive development rights for two candidate substances, including a long-acting semaglutide-based obesity treatment. Under the agreement, Samsung Bioepis will pay an upfront fee and milestone-based technology payments. Both companies have also agreed to grant priority negotiation rights for the development of three additional new drug candidates in the future.

On the same day, Samsung Epis Holdings also entered into an agreement to invest in 20 billion won worth of convertible bonds (CB) issued by G2G Bio. Through this, the companies have established not only a strategic partnership but also a financial investment relationship.

Kyungah Kim, CEO of Samsung Epis Holdings, stated, "This agreement will serve as an opportunity to expand our drug development capabilities by maximizing synergy among affiliates under the holding company structure."

Heeyong Lee, CEO of G2G Bio, commented, "The development of obesity treatment candidates will proceed with global development costs borne by our partners. Going forward, we plan to secure a global supply base in connection with the expansion of our production facilities."

This content was produced with the assistance of AI translation services.